Ovid Therapeutics Inc. (OVID) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Ovid Therapeutics Inc. (OVID) Earnings Overview
As of June 23, 2026, Ovid Therapeutics Inc. (OVID) reported trailing twelve-month net income of -$24M, reflecting +35.1% year-over-year growth. The company earned $-0.33 per diluted share over the past four quarters, with a net profit margin of -240.1%.
Looking at the long-term picture, OVID's historical earnings data spans multiple years. The company achieved its highest annual net income of $123M in fiscal 2021.
Ovid Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), PRAX (-$327M net income), LGND ($154M net income, 46.4% margin), OVID has room to improve margins relative to the peer group. Compare OVID vs ACAD →
OVID Earnings vs Peers
Earnings metrics vs comparable public companies
OVID Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$17M | +34.1% | -$42M | $-0.24 | -240.1% | -585.2% |
| 2024 | -$26M | +49.5% | -$62M | $-0.37 | -4670.1% | -10933.7% |
| 2023 | -$52M | +3.4% | -$59M | $-0.74 | -13351.8% | -15122.7% |
| 2022 | -$54M | -144.1% | -$56M | $-0.77 | -3604.7% | -3696.4% |
| 2021 | $123M | +251.6% | $124M | $1.76 | 58.9% | 59.6% |
| 2020 | -$81M | -34.0% | -$81M | $-1.39 | -642.3% | -645.4% |
| 2019 | -$60M | -16.3% | -$61M | $-1.51 | - | - |
| 2018 | -$52M | +19.8% | -$53M | $-2.11 | - | - |
| 2017 | -$65M | -189.1% | -$65M | $-3.35 | - | - |
| 2016 | -$22M | -70.3% | -$23M | $-1.14 | - | - |
| 2015 | -$13M | -2844.1% | -$13M | $-0.67 | - | - |
| 2014 | $-447,000 | - | $-447,000 | $-0.09 | - | - |
Download Data
Export OVID earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OVID — Frequently Asked Questions
Quick answers to the most common questions about buying OVID stock.
What is OVID earnings per share (EPS)?
OVID trailing twelve-month (TTM) diluted EPS is $-0.33, reflecting +35.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is Ovid Therapeutics Inc.'s net income?
Ovid Therapeutics Inc. (OVID) trailing twelve-month net income is $-24M as of 2025. Earnings grew +35.1% year-over-year.
Is OVID profitable?
OVID is not currently profitable on a TTM basis, reporting a net loss of $-24M. Net margin is -240.1%. Investors should monitor for a return to profitability.
What is OVID's earnings growth rate?
OVID compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are OVID's profit margins?
Ovid Therapeutics Inc. net profit margin is -240.1%, operating margin is -585.2%, and gross margin is +95.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -17.5%.
Is OVID growing earnings?
Yes, OVID earnings are accelerating — EPS growth of +35.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-24M. Earnings momentum is strengthening.
What was OVID's best earnings year?
Ovid Therapeutics Inc.'s highest annual net income on record is $123M, achieved in fiscal year 2021. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were OVID's earnings last quarter?
OVID's most recent reported quarter was Q1 2026. Net income was $-17M with diluted EPS of $-0.23. For a full breakdown of all quarters, see the quarterly earnings table on this page.